Drugs / URABRELIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03512340 | Mar 2018 → Sep 2020 | hematopoietic and lymphoid cell neoplasm, high grade malignant neoplasm | Surface Oncology | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | URABRELIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594610 ↗ |
| Known as | SRF231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03512340 ↗ |
| Action | Inhibit | “SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha” NCT03512340 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4594610 ↗ |